Rockefeller Capital Management’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q4 | – | Sell |
-1,037,763
| Closed | -$19.2M | – | 1616 |
|
|
2023
Q3 | $19.2M | Buy |
1,037,763
+260,361
| +33% | +$2.95M | 0.07% | 270 |
|
|
2023
Q2 | $8.6M | Buy |
777,402
+41,914
| +6% | +$584K | 0.03% | 478 |
|
|
2023
Q1 | $9.88M | Buy |
735,488
+170,303
| +30% | +$2.95M | 0.04% | 408 |
|
|
2022
Q4 | $6.99M | Buy |
565,185
+28,421
| +5% | +$402K | 0.04% | 459 |
|
|
2022
Q3 | $7.49M | Buy |
536,764
+17,042
| +3% | +$274K | 0.04% | 439 |
|
|
2022
Q2 | $7.18M | Buy |
519,722
+30,370
| +6% | +$486K | 0.04% | 430 |
|
|
2022
Q1 | $7.96M | Buy |
489,352
+101,002
| +26% | +$1.58M | 0.04% | 425 |
|
|
2021
Q4 | $6.33M | Buy |
388,350
+51,209
| +15% | +$863K | 0.03% | 477 |
|
|
2021
Q3 | $5.01M | Buy |
337,141
+158,653
| +89% | +$2.54M | 0.03% | 480 |
|
|
2021
Q2 | $3.56M | Buy |
178,488
+178,288
| +89,144% | +$3.53M | 0.02% | 546 |
|
|
2021
Q1 | $4K | Hold |
200
| – | – | ﹤0.01% | 2987 |
|
|
2020
Q4 | $4K | Hold |
200
| – | – | ﹤0.01% | 2525 |
|
|
2020
Q3 | $8K | Hold |
200
| – | – | ﹤0.01% | 2097 |
|
|
2020
Q2 | $10K | Hold |
200
| – | – | ﹤0.01% | 1909 |
|
|
2020
Q1 | $13K | Buy |
+200
| New | +$18K | ﹤0.01% | 1673 |
|
Rockefeller Capital Management's ICPT Position: Q4 2023 in Review
Rockefeller Capital Management sold out of Intercept Pharmaceuticals, Inc. (ICPT) in Q4 2023, closing a stake of 1,037,763 shares — an estimated $19.2M sold.
Rockefeller Capital Management first reported a position in ICPT in Q1 2020 and held it in 15 quarters. The position peaked at $19.2M in Q3 2023. 0 funds tracked by Wall St. Rank hold ICPT as of Q4 2023.
- Rockefeller Capital Management reported no remaining Intercept Pharmaceuticals, Inc. position as of Q4 2023 after selling out during the quarter.
- Rockefeller Capital Management sold 1,037,763 Intercept Pharmaceuticals, Inc. shares in Q4 2023, an estimated $19.2M.
- Rockefeller Capital Management first reported a position in Intercept Pharmaceuticals, Inc. in Q1 2020 and held it in 15 quarters.
- Rockefeller Capital Management's Intercept Pharmaceuticals, Inc. position peaked at $19.2M in Q3 2023.
- 0 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q4 2023.
Based on Rockefeller Capital Management's 13F filing for Q4 2023, filed 14 Feb 2024.